As of 2025-06-22, the Intrinsic Value of Collegium Pharmaceutical Inc (COLL) is 43.46 USD. This COLL valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 29.83 USD, the upside of Collegium Pharmaceutical Inc is 45.70%.
The range of the Intrinsic Value is 17.10 - 175.28 USD
Based on its market price of 29.83 USD and our intrinsic valuation, Collegium Pharmaceutical Inc (COLL) is undervalued by 45.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 17.10 - 175.28 | 43.46 | 45.7% |
| DCF (Growth 10y) | 70.70 - 433.33 | 131.33 | 340.3% |
| DCF (EBITDA 5y) | 141.37 - 177.65 | 156.07 | 423.2% |
| DCF (EBITDA 10y) | 181.02 - 248.93 | 209.38 | 601.9% |
| Fair Value | 34.14 - 34.14 | 34.14 | 14.46% |
| P/E | 23.95 - 56.94 | 39.03 | 30.9% |
| EV/EBITDA | 126.90 - 196.08 | 176.95 | 493.2% |
| EPV | (15.60) - (12.86) | (14.23) | -147.7% |
| DDM - Stable | 17.50 - 92.78 | 55.14 | 84.8% |
| DDM - Multi | 56.72 - 235.63 | 91.64 | 207.2% |
| Market Cap (mil) | 958.74 |
| Beta | 0.15 |
| Outstanding shares (mil) | 32.14 |
| Enterprise Value (mil) | 1,700.25 |
| Market risk premium | 4.60% |
| Cost of Equity | 7.39% |
| Cost of Debt | 9.69% |
| WACC | 7.16% |